CD45-ADC conditioning enables efficient engraftment in multiple peripheral tissues. (A) Schematic depiction of the experimental design for CD45-ADC treatment and ubiquitin-GFP HSCT. (B) Representative flow plots showing the degree of GFP chimerism in the peripheral blood and bone marrow, 6 weeks after CD45-ADC treatment and HSCT. (C) Bar graphs displaying the flow cytometric analysis of GFP chimerism in peripheral blood and bone marrow cell subsets, 6 weeks after CD45-ADC treatment and HSCT. (D) Flow cytometric analysis plots representative of hematopoietic GFP chimerism in the brain, liver, lung, and skin, 6 weeks after treatment with CD45-ADC and HSCT. (E) The GFP chimerism in various myeloid cell populations in the brain, liver, lung, and skin, as assessed by flow cytometry, 6 weeks after CD45-ADC and HSCT, summarized in bar graphs. CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; Inter. macrophages^High, major histocompatibility complex II (MHCII)-high interstitial macrophages; Inter. macrophages^Low, MHCII-low interstitial macrophages; MEP, megakaryocyte-erythroid progenitor.